Indoco Remedies' Baddi plant gets EU GMP approval from Malta Medicines Authority

Indoco Remedies' Baddi plant gets EU GMP approval from Malta Medicines Authority

By: IPP Bureau

Last updated : May 15, 2026 7:17 am



The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026


Indoco Remedies Ltd. has announced that its manufacturing facility for solid oral dosage forms (Unit I) located at Baddihas received EU GMP certification from the Malta Medicines Authority.

The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026. The approval confirms that the facility complies with Good Manufacturing Practice (GMP) requirements as outlined under the EC Directive.

The development strengthens Indoco’s regulatory standing in international markets and reinforces its commitment to maintaining globally accepted manufacturing and quality standards.

Aditi Panandikar, Managing Director of Indoco Remedies Ltd., said, “This approval from the Malta Medicine Authority further reflects Indoco’s strong commitment to quality, compliance and adherence to global regulatory standards. We are focused on maintaining the highest quality standards while catering to our customers in India and globally.”

The Baddi facility manufactures solid oral dosage formulations and plays a significant role in the company’s domestic and international supply operations. The EU GMP certification is expected to further support Indoco’s presence in regulated markets.

 

Indoco Remedies Ltd. Malta Medicines Authority EU GMP certification Baddi facility pharmaceutical manufacturing solid oral dosage GMP compliance EC Directive regulatory approval pharma quality standards global regulatory standards Indian pharma manufacturing facility Aditi Panandikar pharma exports quality compliance EU regulations pharmaceutical industry GMP standards drug manufacturing

First Published : May 15, 2026 12:00 am